Advancements in Treating Metastatic Gastric Cancer

This chapter explores the recent approval of zolbituximab for clodin-18 isoform 2 positive metastatic gastric cancers, based on the 2023 Spotlight trial results. It examines the trial's outcomes, including the benefits and potential side effects of the new treatment compared to placebo.